|Bid||0.4424 x 800|
|Ask||0.4900 x 800|
|Day's range||0.4040 - 0.4730|
|52-week range||0.4040 - 4.0000|
|Beta (5Y monthly)||1.72|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2022 - 18 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.82|
Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.
The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.